Skip to main content

Dopamine Transporter Scan (DaTscan)

  • Chapter
  • First Online:
Book cover Clinical Nuclear Medicine Neuroimaging
  • 605 Accesses

Abstract

Dopamine transporter scan (DaTscan), as the name implies, is a brain SPECT imaging modality with 123I-ioflupane as the radioactive tracer that has a high binding affinity to striatal dopamine transporters. In 2011, FDA approved the clinical use of DaTscan in the US to help differentiate essential tremor (ET) from tremor due to Parkinson’s disease (PD), multiple system atrophy (MSA), or progressive supranuclear palsy (PSP). Such differentiation could be crucial for certain patients’ clinical diagnosis, choice of pharmacotherapy, and prognostic evaluation (Booij et al., Q J Nucl Med Mol Imaging 56:17–26, 2012; Davidsson et al., Ann Nucl Med 28(9):851–859, 2014; Gayed et al., Clin Nucl Med 40(5):390–393, 2015). A normal DaTscan is characterized by crescent-shaped tracer activity with highest tracer intensity in caudate nuclei tapering into putamen body and tail in both hemispheres. Since dopamine neurons in putamen are more vulnerable to neurodegenerative insults compared to those in caudate nuclei, an abnormal DaTscan manifests asymmetrically decreased tracer activity due to striatal dopamine neuron loss, depending on disease staging, typically initial affecting one of the putamens and then spreading into the contralateral putamen and/or the ipsilateral caudate nuclei and finally the caudate nuclei on both sides (Brooks, Parkinsonism Relat Disord 18S1:S31–S33, 2012; Meles et al., J Nucl Med 58:23–28, 2017; Pagano et al., Clin Med (Lond) 16(4):371–375, 2016). This unique neuroimaging pattern not only helps diagnose PD, but also assists in the differentiation of PD from Parkinsonism associated with or caused by other neurodisorders. Presented in this chapter are selected cases with probable normal DaTscan in patients with ET or neuroleptic-induced Parkinsonism, and abnormal DaTscans due to a variety of underlying causes, including probable early and advanced idiopathic PD, cerebrovascular accident (CVA)/stroke, arteriovenous malformation (AVM), corticobasal degeneration (CBD), PSP, and MSA.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Booij J, Teune LK, Verberne HJ. The role of molecular imaging in the differential diagnosis of parkinsonism. Q J Nucl Med Mol Imaging. 2012;56:17–26.

    PubMed  CAS  Google Scholar 

  2. Brooks DJ. Parkinson’s disease: diagnosis. Parkinsonism Relat Disord. 2012;18S1:S31–3.

    Article  Google Scholar 

  3. Davidsson A, Georgiopoulos C, Dizdar N, et al. Comparison between visual assessment of dopaminergic degeneration pattern and semi-quantitative ratio calculations in patients with Parkinson’s disease and atypical Parkinsonian syndromes using DaTSCAN SPECT. Ann Nucl Med. 2014;28(9):851–9.

    Article  CAS  Google Scholar 

  4. Gayed I, Joseph U, Fanous M, et al. The impact of DaTSCAN in the diagnosis of Parkinson disease. Clin Nucl Med. 2015;40(5):390–3.

    Article  Google Scholar 

  5. Kuo PH, Lei HH, Avery R, et al. Evaluation of an objective striatal analysis program for determining laterality in uptake of I-123-ioflupane SPECT images: comparison to clinical symptoms and to visual reads. J Nucl Med Technol. 2014;42(2):105–8.

    Article  Google Scholar 

  6. Ling H. Clinical approach to progressive supranuclear palsy. J Mov Disord. 2016;9(1):3–13.

    Article  Google Scholar 

  7. La M, Micallef C, Paviour DC, et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2012;27:1754–62.

    Article  Google Scholar 

  8. Meles SK, Tenue LK, de Jong BM, et al. Metabolic imaging in Parkinson disease. J Nucl Med. 2017;58:23–8.

    Article  CAS  Google Scholar 

  9. Ogawa T, Fujii S, Kuya K, et al. Role of neuroimaging on differentiation of Parkinson’s disease and its related disease. Yonago Acta Medica. 2018;61:145–55.

    Article  CAS  Google Scholar 

  10. Pagano G, Niccolini F, Politis M. Imaging in Parkinson’s disease. Clin Med (Lond). 2016;16(4):371–5.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dafang Wu MD, PhD .

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wu, D. (2020). Dopamine Transporter Scan (DaTscan). In: Clinical Nuclear Medicine Neuroimaging . Springer, Cham. https://doi.org/10.1007/978-3-030-40893-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-40893-0_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-40892-3

  • Online ISBN: 978-3-030-40893-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics